Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Genprex, Inc. | Chief Medical Officer | Common Stock | 4.81K | $258K | $1.06 | Feb 18, 2024 | Direct |
Actinium Pharmaceuticals, Inc. | Chief Medical Officer | Stock Option (Right to Buy) | 67.2K | Sep 1, 2021 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
GNPX | Genprex, Inc. | Feb 18, 2024 | 1 | -$5.8K | 4 | Feb 21, 2024 | Chief Medical Officer |
GNPX | Genprex, Inc. | Feb 18, 2023 | 1 | $0 | 4 | Feb 22, 2023 | Chief Medical Officer |
GNPX | Genprex, Inc. | Feb 4, 2022 | 1 | $0 | 4 | Feb 8, 2022 | Chief Medical Officer |
GNPX | Genprex, Inc. | Sep 27, 2021 | 1 | $0 | 4 | Sep 28, 2021 | Chief Medical Officer |
GNPX | Genprex, Inc. | Sep 27, 2021 | 0 | $0 | 3 | Sep 28, 2021 | Chief Medical Officer |
ATNM | Actinium Pharmaceuticals, Inc. | Sep 1, 2021 | 1 | $0 | 4 | Sep 3, 2021 | Chief Medical Officer |